Adenocarcinoma

"Adenocarcinoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A malignant epithelial tumor with a glandular organization.

Descriptor ID	D000230
MeSH Number(s)	C04.557.470.200.025
Concept/Terms	Adenocarcinoma Adenocarcinoma Adenocarcinomas Adenoma, Malignant Adenomas, Malignant Malignant Adenoma Malignant Adenomas Carcinoma, Granular Cell Carcinoma, Granular Cell Carcinomas, Granular Cell Granular Cell Carcinoma Granular Cell Carcinomas Adenocarcinoma, Granular Cell Adenocarcinomas, Granular Cell Granular Cell Adenocarcinoma Granular Cell Adenocarcinomas Adenocarcinoma, Tubular Adenocarcinoma, Tubular Adenocarcinomas, Tubular Tubular Adenocarcinoma Tubular Adenocarcinomas Carcinoma, Tubular Carcinomas, Tubular Tubular Carcinoma Tubular Carcinomas Carcinoma, Cribriform Carcinoma, Cribriform Carcinomas, Cribriform Cribriform Carcinoma Cribriform Carcinomas Adenocarcinoma, Basal Cell Adenocarcinoma, Basal Cell Adenocarcinomas, Basal Cell Basal Cell Adenocarcinoma Basal Cell Adenocarcinomas Adenocarcinoma, Oxyphilic Adenocarcinoma, Oxyphilic Adenocarcinomas, Oxyphilic Oxyphilic Adenocarcinoma Oxyphilic Adenocarcinomas

Below are MeSH descriptors whose meaning is more general than "Adenocarcinoma".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Neoplasms, Glandular and Epithelial [C04.557.470]
Carcinoma [C04.557.470.200]
Adenocarcinoma [C04.557.470.200.025]

Below are MeSH descriptors whose meaning is related to "Adenocarcinoma".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Adenocarcinoma" by people in this website by year, and whether "Adenocarcinoma" was a major or minor topic of these publications.

Bar chart showing 786 publications over 30 distinct years, with a maximum of 50 publications in 2003

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	13	6	19
1996	20	4	24
1997	23	4	27
1998	32	4	36
1999	35	5	40
2000	28	15	43
2001	28	3	31
2002	29	5	34
2003	41	9	50
2004	25	13	38
2005	36	8	44
2006	28	4	32
2007	28	13	41
2008	29	9	38
2009	22	2	24
2010	20	6	26
2011	35	4	39
2012	22	5	27
2013	14	3	17
2014	27	3	30
2015	17	2	19
2016	16	2	18
2017	17	3	20
2018	11	0	11
2019	7	1	8
2020	10	3	13
2021	11	0	11
2022	12	0	12
2023	9	0	9
2024	5	0	5

Below are the most recent publications written about "Adenocarcinoma" by people in Profiles.

Ajmal N, Deng Y, Kenyon LC, Curtis MT, Dispagna M, Izes J, Li L. Metastatic prostate adenocarcinoma to the brain - a clinicopathologic analysis of 21 cases. Diagn Pathol. 2024 Oct 01; 19(1):132.

View in: PubMed
Su SH, Mitani Y, Li T, Sachdeva U, Flashner S, Klein-Szanto A, Dunbar KJ, Abrams J, Nakagawa H, Gabre J. Lactate Suppresses Growth of Esophageal Adenocarcinoma Patient-Derived Organoids through Alterations in Tumor NADH/NAD+ Redox State. Biomolecules. 2024 Sep 22; 14(9).

View in: PubMed
Nadeem MS, Ali U, Khan A, Wajid I, Riaz O, Azeem MT. Response of various histological types of locally advanced rectal cancer to neoadjuvant multimodality therapy. J Pak Med Assoc. 2024 Jul; 74(7):1240-1244.

View in: PubMed
Naranjo NM, Kennedy A, Testa A, Verrillo CE, Altieri AD, Kean R, Hooper DC, Yu J, Zhao J, Abinader O, Pickles MW, Hawkins A, Kelly WK, Mitra R, Languino LR. Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma. Cancer Biol Ther. 2024 Dec 31; 25(1):2364433.

View in: PubMed
Poiset SJ, Shah S, Cappelli L, Ann? P, Mooney KE, Werner-Wasik M, Laufer TS, Posey JA, Lin D, Basu Mallick A, Lavu H, Bashir B, Yeo CJ, Mueller AC. Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma. Radiat Oncol. 2024 May 29; 19(1):65.

View in: PubMed
Jirka GW, Lefler DS, Russo J, Bashir B. Colon adenocarcinoma and Birt-Hogg-Dub? syndrome in a young patient: case report and exploration of pathologic implications. Cancer Biol Ther. 2023 Dec 31; 24(1):2184153.

View in: PubMed
Samaratunga H, Egevad L, Yaxley J, Perry-Keene J, Le Fevre I, Kench J, Matsika A, Bostwick D, Iczkowski K, Delahunt B. Gleason score 3+3=6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patients. Pathology. 2024 Feb; 56(1):33-38.

View in: PubMed
Micaily I, Blais EM, Carhart R, Lam S, Cohen SJ, Cannaday SJ, Halverson D, Matrisian LM, DeArbeloa P, Thach D, Petricoin E, Pishvaian MJ, Lavu H, Yeo CJ, Mallick AB. Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy. JCO Precis Oncol. 2023 Sep; 7:e2200648.

View in: PubMed
Zager Y, Goldes Y, Assaf D, Zilka N, Anteby R, Nevo Y, Barda L, Nevler A. Neutrophil to Lymphocyte Ratio in Patients Who Received Neoadjuvant Treatment before Gastrectomy. Isr Med Assoc J. 2023 May; 25(5):336-340.

View in: PubMed
Asif B, Sarvestani AL, Gamble LA, Samaranayake SG, Famiglietti AL, Fasaye GA, Quezado M, Miettinen M, Korman L, Koh C, Heller T, Davis JL. Cancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer: a prospective cohort study. Lancet Oncol. 2023 04; 24(4):383-391.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement